Lexion Medical, LLC v. Northgate Technologies, Inc.

641 F.3d 1352, 98 U.S.P.Q. 2d (BNA) 1388, 2011 U.S. App. LEXIS 8299, 2011 WL 1518895
CourtCourt of Appeals for the Federal Circuit
DecidedApril 22, 2011
Docket2009-1494
StatusPublished
Cited by70 cases

This text of 641 F.3d 1352 (Lexion Medical, LLC v. Northgate Technologies, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Lexion Medical, LLC v. Northgate Technologies, Inc., 641 F.3d 1352, 98 U.S.P.Q. 2d (BNA) 1388, 2011 U.S. App. LEXIS 8299, 2011 WL 1518895 (Fed. Cir. 2011).

Opinion

*1354 RADER, Chief Judge.

The United States District Court for the Northern District of Illinois entered summary judgment that Defendants-Appellants Northgate Technologies, Inc., Smith & Nephew, Inc., and Linvatec Corp. (collectively, “Northgate”) infringe United States Patent No. 5,411,474 (“'474 patent”). Lexion Med., LLC. v. Northgate Techs., 618 F.Supp.2d 896 (N.D.Ill.2009). Contesting this judgment, Northgate questions the district court’s construction of the claim limitation “having a temperature within 2°C of the predetermined temperature.” Because the record amply supports the trial court’s interpretation of this claim term and we find no genuine issue of material fact regarding infringement, this court affirms.

I

To create more working space during laparoscopic procedures, surgeons inflate the abdominal cavity with gas. Traditionally, an insufflator directly pumped gases used for laparoscopic procedures through a tube and into a patient’s body. The gases were relatively cold (generally at least 17°C below body temperature), '474 patent col.l 11.63-64, and dry (200 parts per million or less of water vapor), id. at col.2 11.35-36.

Because of the cold and dry gas, patients could experience post-operative shivering and shoulder pain as a common side effect of laparoscopic procedures. To minimize this side effect, the '474 patent discloses and claims an apparatus for heating and humidifying gas to a predetermined and preset temperature for use during laparoscopic procedures. Id. at col.3 11.44— 48.

The claimed apparatus aims to deliver gas “within 2°C of the predetermined temperature.” Id. at col.4 11.31-32. For example, the patent provides for gas being delivered “while still maintained at the desired temperature, or at least within about 2°C of it, and preferably within about 0.5°C[.]” Id. at col.9 11.28-30. The specification also states that upon activation “there is a lag time of milliseconds for sensing the temperature of gas and adjusting the heating to achieve the proper gas temperature .... [and that] approximately the first 12 to 15 cubic centimeters of gas leaving the apparatus after it is activated are cooler than the predetermined temperature.” Id. at col.9 11.49-55.

Claims 11 and 12 of the '474 patent are at issue in this appeal. Claim 11 states:

11. A method of providing heated, humidified gas into a patient for an endoscopic procedure comprising the steps of:
a) directing pressure- and volumetric flow rate-controlled gas, received from an insufflator into a chamber having a means for heating the gas to a temperature within a predetermined range and a means for humidifying the gas and being disposed immediately adjacent to the patient, wherein the chamber is in flow communication with and immediately adjacent to a means for delivering the gas to the interior of the patient;
b) sensing the temperature of the gas as it exits the chamber to determine if it is within the predetermined range; and
c) actuating the heating means if the temperature of the gas is without the predetermined range;
d) humidifying the gas within the chamber; and
e) flowing the gas into the delivery means such that the gas enters the patient humidified and having a temperature within 2°C of the predetermined temperature and thus providing the gas.

Id. at col.12 11.43-65 (emphasis added). Dependant claim 12 requires:

*1355 12. The method of claim 11, wherein the heating means and the humidifying means heat and humidify the gas simultaneously.

Id. at col.1211.66-68 (emphasis added).

Northgate’s accused Humi-Flow device heats and humidifies gas from an insufflator. Gas from the insufflator passes through a tube connected to an inlet leading into the Humi-Flow’s chamber. The gas is heated and humidified before being pushed through the Humi-Flow’s outlet, into a tube, and then into a patient’s body.

The Humi-Flow indirectly heats gas flowing through it. Heating elements within the Humi-Flow raise the temperature of a heater core. Gas passing through the Humi-Flow is heated through contact with that heater core. By maintaining the heater core at 70°C the passing gas is heated to 37°C.

The Plaintiff-Appellee Lexion Medical, LLC (“Lexion”) sued Northgate for infringement of both claims 11 and 12 of the '474 patent for making and selling its Humi-Flow device.

II

This case has previously appeared before this court. Lexion Med., LLC. v. Northgate Techs., Inc., 292 Fed.Appx. 42 (Fed.Cir.2008) (“Lexion I ”). In Lexion I, this court, inter alia, vacated the district court’s judgment of infringement of the '474 patent and remanded with new constructions of the claim limitations “means for humidifying,” “means for heating,” and “predetermined temperature.” Id. at 51-52. On remand, as noted, the district court granted Lexion’s motion for summary judgment of infringement.

At the trial preceding Lexion I, Dr. John Burban (“Burban”) provided expert testimony that the Humi-Flow released gas “having a temperature within 2°C of the predetermined temperature.” The district court did not construe “predetermined temperature.” Burban’s first declaration and data were premised on a proposed construction of “predetermined temperature” later rejected by this court in Lexion I.

Burban conducted two sets of experiments (“Test 1” and “Test 2”) to measure the temperature of gas heated by the Humi-Flow. These tests took temperature readings at the outlet, or exit, of the Humi-Flow, and at the exit of a trocar, or tube, leading to a water bath. The only difference between Test 1 and Test 2 was trocar placement.

Burban’s first declaration analyzed data collected from both Test 1 and Test 2. Burban’s analysis showed that the temperature range of gases coming from the Humi-Flow fit within Lexion’s initial “range of range” construction of “predetermined temperature” and also satisfied “having a temperature within 2°C of the predetermined temperature.” Lexion’s “range of range” construction of “predetermined temperature” explained that the claimed device was set to a predetermined temperature that was not a single temperature point, but was within a range of temperatures. With this construction of “predetermined temperature,” Lexion argued that the 2°C range in limitation (e) meant within 2°C of the predetermined temperature range, “a range of a range.”

At the trial preceding Lexion I, the jury returned a special verdict that Northgate induced and contributed to the infringement of the '474 patent. Lexion Med., LLC. v. Northgate Techs. Inc, No. 1:04-CV-5705, slip op. at 1 (N.D.Ill. Feb. 12, 2007). The district court denied Northgate’s motion for Judgment as a Matter of Law and entered judgment for Lexion. Id. at 3-4.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
641 F.3d 1352, 98 U.S.P.Q. 2d (BNA) 1388, 2011 U.S. App. LEXIS 8299, 2011 WL 1518895, Counsel Stack Legal Research, https://law.counselstack.com/opinion/lexion-medical-llc-v-northgate-technologies-inc-cafc-2011.